venerdì, 31 marzo 2023
13 Luglio 2018

FDA Grants Orphan Drug Designation to CPI-613 for Treatment of Burkitt Lymphoma

July 11, 2018 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to CPI-613 for the treatment of Burkitt lymphoma. Burkitt lymphoma is a highly aggressive hematologic B-cell malignancy classically characterized by the overexpression of c-Myc. Due to the rapid proliferation rate of these tumors, the mainstay of treatment includes aggressive chemotherapy and immunotherapy. As per the National Comprehensive Cancer Network® … (leggi tutto)